Connect your AI

Anika Therapeutics ANIK Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

AVN

AVNSAVNS

$300K+101%

Globus MedicalGMED

——

Envista Holdings CorporationNVST

——

Other financials

Income statement

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's increase (decrease) in accounts receivable?: Anika Therapeutics (ANIK) reported increase (decrease) in accounts receivable of $3.23M in Q2 2026.